Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
hanmipharm.com

See what CB Insights has to offer

Investments

4

Portfolio Exits

1

Partners & Customers

10

About Hanmi Pharmaceutical

Hanmi Pharmaceutical (KRX: 008930) is a South Korea-based pharmaceutical company that focuses on the development of biologics, chemical entities, and drugs.

Hanmi Pharmaceutical Headquarter Location

14, Wiryeseong-daero Songpa-gu

Seoul, 05545,

South Korea

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Hanmi Pharmaceutical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Hanmi Pharmaceutical Rank

Latest Hanmi Pharmaceutical News

Hanmi Pharmaceutical to Speed up Production of Generic Version of Merck & Co.'s COVID-19 Pill

Jan 21, 2022

Hanmi Pharmaceutical to Speed up Production of Generic Version of Merck & Co.'s COVID-19 Pill Share Hanmi Pharmaceutical to Speed up Production of Generic Version of Merck & Co.'s COVID-19 Pill By Choi Moon-hee   Hanmi Pharmaceutical will speed up the production of a generic version of Merck & Co.'s COVID-19 pill for supply to 105 low- and middle-income countries. Hanmi Pharmaceutical announced on Jan. 20 that it will speed up the production of a generic version of Merck & Co.'s COVID-19 pill, molnupiravir (product name: Lagevrio), for supply to 105 low- and middle-income countries. Hanmi Pharmaceutical is one of the three Korean generic drug manufacturers that signed sublicense agreements with the Medicines Patent Pool (MPP), a U.N.-backed public health organization, to produce Merck & Co.'s oral antiviral medication. The two other companies are Celltrion Inc. and Dongbang FTL. Molnupiravir was approved for emergency use in the United Kingdom in November 2021. The MPP has selected 27 drugmakers around the world to produce low-cost versions of molnupiravir for low- and medium-income countries. Hanmi Pharmaceutical submitted a letter of intent to participate in the project to the MPP in November 2021. The Korean drugmaker was finally selected as a production manager in December 2021. Under the contract, Hanmi Precision Chemical, an affiliate of Hanmi Pharmaceutical, will produce raw materials for molnupiravir, while Hanmi Pharmaceutical will produce finished drugs. Hanmi Pharmaceutical will receive molnupiravir manufacturing technology from MSD. Patent royalties will be exempted until the WHO declares the end of the pandemic. POPULAR

Hanmi Pharmaceutical Investments

4 Investments

Hanmi Pharmaceutical has made 4 investments. Their latest investment was in Spectrum Pharmaceuticals as part of their Corporate Minority - P2P on January 1, 2022.

CBI Logo

Hanmi Pharmaceutical Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/4/2022

Corporate Minority - P2P

Spectrum Pharmaceuticals

$20M

Yes

2

3/29/2016

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

1/14/2015

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

12/19/2014

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/4/2022

3/29/2016

1/14/2015

12/19/2014

Round

Corporate Minority - P2P

Seed VC

Corporate Minority

Series B

Company

Spectrum Pharmaceuticals

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$20M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

10

10

10

Hanmi Pharmaceutical Portfolio Exits

1 Portfolio Exit

Hanmi Pharmaceutical has 1 portfolio exit. Their latest portfolio exit was Allegro Ophthalmics on September 23, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/23/2020

Asset Sale

$99M

1

Date

9/23/2020

Exit

Asset Sale

Companies

Valuation

$99M

Acquirer

Sources

1

Hanmi Pharmaceutical Partners & Customers

10 Partners and customers

Hanmi Pharmaceutical has 10 strategic partners and customers. Hanmi Pharmaceutical recently partnered with Aptose Biosciences on November 11, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

11/5/2021

Licensee

Aptose Biosciences

Canada

Hanmi shares rise on $420 mn leukemia drug license deal with Aptose 2021.11.05 10:20

Hanmi Pharmaceutical said in a regulatory filing Thursday afternoon it has entered into an exclusive license agreement with Toronto-headquartered and Nasdaq-listed Aptose Biosciences to develop and commercialize HM43239 designed to target a distinct constellation of kinases operative in myeloid malignancies , including SYK and FLT3 .

3

10/28/2021

Partner

University of Oxford

United Kingdom

Hanmi Science, University of Oxford to co-research infectious diseases

Hanmi Science said that it has entered a pandemic science alliance with the University of Oxford to conduct research to prevent new and mutated infectious diseases .

1

7/23/2021

Partner

LegoChem Biosciences

South Korea

Hanmi Pharm, LegoChem partner to develop bispecific antibody-based ADC2021.07.23 13:13

Hanmi Pharmaceutical , LegoChem Biosciences partner to develop bispecific antibody-based ADC

1

6/29/2021

Licensee

Sanofi

France

Subscribe to see more

Subscribe to see more

10

3/12/2021

Partner

Spectrum Pharmaceuticals

United States

Subscribe to see more

Subscribe to see more

10

Date

11/5/2021

10/28/2021

7/23/2021

6/29/2021

3/12/2021

Type

Licensee

Partner

Partner

Licensee

Partner

Business Partner

Aptose Biosciences

University of Oxford

LegoChem Biosciences

Sanofi

Spectrum Pharmaceuticals

Country

Canada

United Kingdom

South Korea

France

United States

News Snippet

Hanmi shares rise on $420 mn leukemia drug license deal with Aptose 2021.11.05 10:20

Hanmi Pharmaceutical said in a regulatory filing Thursday afternoon it has entered into an exclusive license agreement with Toronto-headquartered and Nasdaq-listed Aptose Biosciences to develop and commercialize HM43239 designed to target a distinct constellation of kinases operative in myeloid malignancies , including SYK and FLT3 .

Hanmi Science, University of Oxford to co-research infectious diseases

Hanmi Science said that it has entered a pandemic science alliance with the University of Oxford to conduct research to prevent new and mutated infectious diseases .

Hanmi Pharm, LegoChem partner to develop bispecific antibody-based ADC2021.07.23 13:13

Hanmi Pharmaceutical , LegoChem Biosciences partner to develop bispecific antibody-based ADC

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

1

1

10

10

Hanmi Pharmaceutical Team

1 Team Member

Hanmi Pharmaceutical has 1 team member, including former Senior Director, Inhwan Bae.

Name

Work History

Title

Status

Inhwan Bae

JW Pharmaceutical

Senior Director

Former

Name

Inhwan Bae

Work History

JW Pharmaceutical

Title

Senior Director

Status

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.